Trial · NCT00726453

The Medtronic RESOLUTE US Clinical Trial

NCT00726453, Not applicable, Completed, Medtronic Vascular; results first posted 2012-05-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Medtronic RESOLUTE US Clinical Trial. Trials, record NCT00726453. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00726453

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Medtronic RESOLUTE US Clinical Trial
NCT number: NCT00726453
Status: Completed
Phases: Not applicable
Enrollment: 1,516 participants, actual
Lead sponsor: Medtronic Vascular
Conditions: Coronary Artery Disease
Interventions: Resolute Zotarolimus-Eluting Coronary Stent
First posted: 2008-08-01
Last updated: 2016-05-23
Results first posted: 2012-05-25

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Target Lesion Failure (TLF)	12 Months	Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods.
Secondary	Target Vessel Failure (TVF)	12 months	Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods).
Secondary	Major Adverse Cardiac Event (MACE)	12 months	Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods).
Secondary	Death	12 months
Secondary	Target Vessel MI	12 months	Target Vessel MI (as determined by extended historical and ARC definitions).
Secondary	Stent Thrombosis (ST)	12 months	Stent Thrombosis (ST) (as determined by historic and ARC definitions).

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Target Lesion Failure (TLF)	12 Months	percentage of participants	NUMBER
SECONDARY	Target Vessel Failure (TVF)	12 months	percentage of participants	NUMBER
SECONDARY	Major Adverse Cardiac Event (MACE)	12 months	percentage of participants	NUMBER
SECONDARY	Death	12 months	percentage of participants	NUMBER
SECONDARY	Target Vessel MI	12 months	percentage of eligible participants	NUMBER
SECONDARY	Stent Thrombosis (ST)	12 months	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Target Lesion Failure (TLF)	Primary Enrollment Group	4.7	percentage of participants
Target Vessel Failure (TVF)	Primary Enrollment Group	6.3	percentage of participants
Major Adverse Cardiac Event (MACE)	Primary Enrollment Group	5.5	percentage of participants
Death	Primary Enrollment Group	1.3	percentage of participants
Target Vessel MI	Primary Enrollment Group	1.4	percentage of eligible participants
Stent Thrombosis (ST)	Primary Enrollment Group	0.1	percentage of participants

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Primary Enrollment Group	STARTED	Primary Enrollment Group	1,402
Primary Enrollment Group	STARTED	38 mm Length Sub-study	0
Primary Enrollment Group	COMPLETED	Primary Enrollment Group	1,371
Primary Enrollment Group	COMPLETED	38 mm Length Sub-study	0
Primary Enrollment Group	NOT COMPLETED	Primary Enrollment Group	31
Primary Enrollment Group	NOT COMPLETED	38 mm Length Sub-study	0
38 mm Length Group	STARTED	Primary Enrollment Group	0
38 mm Length Group	STARTED	38 mm Length Sub-study	114
38 mm Length Group	COMPLETED	Primary Enrollment Group	0
38 mm Length Group	COMPLETED	38 mm Length Sub-study	111

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events584

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Angina Pectoris	Cardiac disorders	Primary Enrollment Group	171	1,402	212
other	Angina Pectoris	Cardiac disorders	38 mm Length Sub-Study	16	114	20
other	Nausea	Gastrointestinal disorders	Primary Enrollment Group	0	1,402	0
other	Nausea	Gastrointestinal disorders	38 mm Length Sub-Study	10	114	10
other	Chest Pain	General disorders	Primary Enrollment Group	204	1,402	256
other	Chest Pain	General disorders	38 mm Length Sub-Study	23	114	32
other	Fatigue	General disorders	Primary Enrollment Group	0	1,402	0
other	Fatigue	General disorders	38 mm Length Sub-Study	8	114	8
other	Non-Cardiac Chest Pain	General disorders	Primary Enrollment Group	0	1,402	0
other	Non-Cardiac Chest Pain	General disorders	38 mm Length Sub-Study	10	114	11

1 to 10 of 584Source ClinicalTrials.gov

See all 584 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Primary Enrollment Group
Total, all-cause mortality	38 mm Length Sub-Study
Total, other adverse events	Primary Enrollment Group	724	1,402
Total, other adverse events	38 mm Length Sub-Study	67	114
Total, serious adverse events	Primary Enrollment Group	509	1,402
Total, serious adverse events	38 mm Length Sub-Study	71	114

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
21470813	DERIVED	PubMed
21570508	DERIVED	PubMed
23468513	DERIVED	PubMed
23523454	DERIVED	PubMed
24510638	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Primary Enrollment Group vs 38 mm Length Sub-Study: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00726453

GET https://conductscience.org/api/trials/v1/NCT00726453/events?page=2

API reference For AI assistants